CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Diakonos Oncology doses first patients in DOC-RM trial

Trial StartDOC1021Positive
AI Analysis

Summary

Diakonos Oncology has dosed the first patients in its Phase I/II DOC-RM trial evaluating DOC1021 (dubodencel) for refractory melanoma.

Clinical Trial Data

Phase

Phase I/II

Importance:3/10
Sentiment:
0.30
Phase 1/2melanomaimmunotherapytrial initiation
Related Companies

Read the original article

Published by Clinical Trials Arena on August 3, 2026 9:46 AM

Read Original